Pfizer Reported Positive Phase 3 Vitiligo Trial Results
The oral therapy demonstrated significant repigmentation in phase 3 trials, setting the stage for upcoming regulatory reviews.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Would you personally favor using new oral medications to treat chronic autoimmune skin conditions?
Pfizer has released phase 3 trial results for Litfulo as a treatment for nonsegmental vitiligo. The study indicates that the once-daily oral systemic therapy significantly improves facial and total body repigmentation compared to a placebo.
Why it matters
This drug addresses the immune cell signaling pathways that trigger the destruction of melanin-producing cells. By stabilizing the disease and reducing severity, the therapy offers a new systemic approach to managing vitiligo symptoms.
Litfulo demonstrated efficacy in the TRANQUILLO and TRANQUILLO 2 phase 3 trials using 100mg and 50mg once-daily doses. The results measured facial and total body repigmentation compared to a placebo group.
The players
Pfizer
A multinational pharmaceutical corporation focused on the development and production of vaccines and systemic therapies across multiple therapeutic areas.
The details
Litfulo functions through dual selectivity for JAK3, a protein involved in immune signaling, and the TEC family kinases. By inhibiting these targets, the drug modulates the immune response that leads to the destruction of melanocytes, which are the cells responsible for producing melanin pigment in the skin. The therapy is administered as a once-daily oral systemic treatment to achieve this biological effect.
Timeline
October 13, 2026: Trial results were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.
The Tech Race
These results provide the clinical evidence necessary for Pfizer to progress toward market authorization. The development follows the standard reporting cadence of the TRANQUILLO clinical program, which serves as the primary benchmark for the drug's efficacy and safety profile.
The clinical findings represent a milestone for patients seeking non-surgical systemic options for repigmentation. Availability remains pending as the company prepares to submit these findings for official review by regulators in the US and Europe.
The takeaway
The study validates the efficacy of JAK3 and TEC family kinase inhibition for treating vitiligo-related cell destruction. Interested parties should watch for upcoming filings with the US FDA and the European Medicines Agency to track the therapy's path toward potential commercial approval.
Further reading
For more developments in new medical therapies and clinical research, visit our Biotech section.
Live Poll
Would you personally favor using new oral medications to treat chronic autoimmune skin conditions?
